Issued to Bridge Regulatory Affairs, LLC. Application reviewed but not approved; deficiencies must be corrected.
Issued
June 10, 2026Application
NDA 505b1 • 218600
Product
NDA 218600
Company
Bridge Regulatory Affairs, LLC
Stage
Final Decision
Assyro regulatory brief
FreeSource facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
FDA's complete response letter contains source-text evidence related to Labeling, packaging, and proprietary name, Facility inspection and CGMP compliance. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.
Review the exact redacted FDA letter and address each stated deficiency before resubmission.
Open the document workspaceFDA source document
Application reviewed but not approved; deficiencies must be corrected. Requires resubmission addressing deficiencies. FDA issued this letter to Bridge Regulatory Affairs, LLC on June 10, 2026.
NDA 218600 is the application under which FDA issued this complete response letter to Bridge Regulatory Affairs, LLC. The letter is dated June 10, 2026.
FDA will not approve the application in its present form. The sponsor can resubmit after addressing every deficiency listed in the letter — which starts a Class 1 (two-month) or Class 2 (six-month) resubmission review clock — withdraw the application, or request an opportunity for a hearing.